BIOMAT Database Logo BIOMAT Database Logo

The effect of cyclosporine vs FK 506 on glucose metabolism. 1999

T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
Chirurgische Klinik, Humboldt Universität, Berlin, Germany.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
Interactions of FK 506 and cyclosporine metabolism.
December 1991, Transplantation proceedings,
T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
FK 506 versus cyclosporine.
February 1993, Transplantation proceedings,
T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506.
February 1995, Transplantation proceedings,
T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
FK 506 inhibition of cyclosporine metabolism by human liver microsomes.
February 1991, Transplantation proceedings,
T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
Effect of FK 506 on glucose metabolism and insulin secretion in normal rats.
December 1991, Transplantation proceedings,
T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine.
December 1991, Transplantation proceedings,
T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
Nephrotoxity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity.
December 1994, Transplantation proceedings,
T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.
February 1991, Transplantation proceedings,
T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
Effect of FK-506 and cyclosporine on human lymphocyte responses in vitro.
June 1989, Transplantation proceedings,
T Steinmueller, and T Konrad, and S Jonas, and S Tullius, and W O Bechstein, and A Mueller, and K P Platz, and U Neumann, and P Vicini, and G Toffolo, and C Cobelli, and K H Usadel, and P Neuhaus
Effect of FK 506 and cyclosporine on heart allograft survival in rats.
February 1991, Transplantation proceedings,
Copied contents to your clipboard!